Regulation - Pricing

Filter

Current filters:

Pricing

Popular Filters

176 to 200 of 325 results

UK treatment decisions seriously flawed and must not be used in Europe, say researchers

24-01-2013

The Quality Adjusted Life Years (QALY) approach to deciding what medical treatments are available on…

BiotechnologyEuropePharmaceuticalPricingRegulation

Scottish Medicines Consortium backs AstraZeneca/B-MS' Forxiga for type 2 diabetes

14-01-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and partner Bristol-Myers Squibb (NYSE: BMY) of the USA…

AstraZenecaBristol-Myers SquibbDiabetesEuropeForxigaPharmaceuticalPricingRegulation

Russian government may stop foreign drugmakers from state tendering

10-01-2013

The Russian government is considering imposing a ban on the participation of foreign drug producers in…

EuropePharmaceuticalPoliticsPricingProductionRegulation

Added benefit of Almirall's aclidinium bromide is not proven, says Germany's IQWiG

10-01-2013

The drug aclidinium bromide, trade names Eklira, Bretaris from Spain's largest drugmaker Almirall (ALM:…

aclidiniumAlmirallBretaris GenuairEkliraEuropePharmaceuticalPricingRegulationRespiratory and Pulmonary

German drugs watchdog finds "hint of considerable added benefit" for Pfizer's Inlyta

09-01-2013

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit…

BayerEuropeInlytaNexavarOncologyPfizerPharmaceuticalPricingRegulation

UK's NICE final guidance on Novartis' Lucentis for diabetic macular edema positive

03-01-2013

In final draft guidance issued today (4 January), the UK's drug watchdog the National Institute for Health…

EuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

Danish pharma agrees cap on medicine prices for the coming three years

03-01-2013

A three year price-cap agreement on medicine prices has been signed by Denmark's Minister of Health and…

EuropePharmaceuticalPricingRegulation

More transparency on medicine pricing called for by EU parliamentarians

19-12-2012

More transparency and precise time limits for decision-making on pricing and reimbursement of medicines…

EuropeGenericsPharmaceuticalPricingRegulation

Eisai disagrees with Germany's IQWiG report on epilepsy drug Fycompa

19-12-2012

In the assessment report by the German Institute for Quality and Efficiency in Health Care (IQWiG) on…

EisaiEuropeFycompaNeurologicalPharmaceuticalPricingRegulation

Australian review finds more work needed on new anticoagulants

19-12-2012

A report into anticoagulation therapies released yesterday by Australian Minister for Health Tanya Plibersek…

Asia-PacificBoehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulation

UK's NICE says Roche's Avastin not cost effective for advanced ovarian cancer

18-12-2012

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has published…

AvastinBiotechnologyEuropeOncologyPharmaceuticalPricingRegulationRoche

Once again, no proof of added benefit found for Boehringer/Lilly's Trajenta by Germany's IQWiG

13-12-2012

Once again, the German Institute for Quality and Efficiency in Health Care (IQWiG) has found no added…

Boehringer IngelheimDiabetesEli LillyEuropePharmaceuticalPricingRegulationTrajenta

Scottish Medicines Consortium approves Eisai's Fycompa and Novartis' Lucentis for DME

11-12-2012

Japanese drug major Eisai's (TYO: 4523) Fycompa (perampanel), a treatment for partial epilepsy, is now…

EisaiEuropeFycompaLucentisNeurologicalNovartisPharmaceuticalPricingRegulation

UK pharma group slams NICE for failing to recognize nature of discovery and development

07-12-2012

The Association of the British Pharmaceutical Industry (ABPI) yesterday expressed major concern on behalf…

EsbrietEuropeInterMunePharmaceuticalPricingRegulation

UK's NICE draft guidance recommends Bristol-Myers Orencia for RA

06-12-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today (December…

Anti-Arthritics/RheumaticsBristol-Myers SquibbEuropeOrenciaPharmaceuticalPricingRegulation

Moldova's pharmaceutical market over-regulated, study finds

05-12-2012

According to a study recently released by the Soros Foundation Moldova, the Moldavian pharmaceutical…

EuropeGenericsPharmaceuticalPricingRegulation

Novo Nordisk's Ryzodeg passes regulatory hurdle in Japan; diabetes burden review

03-12-2012

Global insulin market leader Novo Nordisk (NOV: N) of Denmark revealed this morning that its Ryzodeg…

Asia-PacificDegludecDiabetesGlobalHealthcareNovo NordiskPharmaceuticalPricingRegulationRyzodegTresiba

UK's NICE initially negative on InterMune's Esbriet for idiopathic pulmonary fibrosis

30-11-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) said yesterday that…

BiotechnologyEsbrietEuropeInterMunePricingRegulationRespiratory and Pulmonary

New Zealand updates on Tracleer and sildenafil listing

21-11-2012

New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with…

ActelionArrow PharmaceuticalsAsia-PacificPharmaceuticalPricingRegulationRespiratory and PulmonarysildenafilTracleer

Australia to add Pfizer's Lyrica to PBS list; call for antibiotic research incentives

18-11-2012

Australia's Health Minister Tanya Plibersek on Friday announced the government's decision to subsidize…

Asia-PacificLyricaPfizerPharmaceuticalPricingRegulationResearch

Gilead HIV drugs Atripla and Truvada to be listed in New Zealand

13-11-2012

Following a consultation, New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval…

Anti-viralsAsia-PacificAtriplaBiotechnologyGilead SciencesPharmaceuticalPricingRegulationTruvada

176 to 200 of 325 results

Back to top